Company
Acrux
ASX:ACR
Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, the company has successfully marketed through licensees a number of products worldwide with emphasis on the United States.
9 stories
Acrux receives FDA approval for generic testosterone topical solution
The FDA has notified Acrux that its Abbreviated New Drug Application submission has been approved and that Acrux can manufacture and market the generic drug.
Acrux sees growth in sales of testosterone solution
Acrux Ltd’s (ASX:ACR) share price has increased after Eli Lilly and Co (NYSE:LLY) achieved global net sales of US$39 million for Axiron topical solution, during the quarter ended 30 September 2016.